Eptifibatide. A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention

Drugs

Volumn 57, Issue 3, 1999, Pages 439-462

  Goa, Karen L ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; LAMIFIBAN; LEFRADAFIBAN; SIBRAFIBAN; STREPTOKINASE; TICLOPIDINE; TIROFIBAN;

ANAPHYLAXIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG PROTEIN BINDING; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; Q WAVE; REVIEW; ST SEGMENT; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; AREA UNDER CURVE; HUMANS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0033056269     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957030-00015     Document Type: Review

References (74)

1. Van de Werf F. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes. Thromb Haemost 1997; 78 (1): 210-3
2. Yun DD, Alpert JS. Acute coronary syndromes. Cardiology 1997; 88: 223-37
3. Keen WD, Savage MP, Fischman DL, et al. Comparison of coronary angiographic findings during the first six hours of non-Q-wave and Q-wave myocardial infarction. Am J Cardiol 1994 Aug 15; 74: 324-8
4. Kristensen SD, Ravn HB, Falk E. Insights into the pathophysiology of unstable coronary artery disease. Am J Cardiol 1997; 89 (5A): 5E-9E
5. Mak K-H, Tan ATH, Chan C, et al. The clinical impact of platelet glycoprotein IIb/IIIa receptor blockade in cardiovascular medicine. Jpn Circ J 1998 Apr; 62: 233-43
6. Davids MR, Doubell AF. Restenosis after coronary angioplasty: a review of the pathogenesis and strategies for prevention. Cardiovasc J S Afr 1995; 6 (3): 149-61
7. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996 Dec; 28: 1643-51
8. Jang Y, Lincoff MA, Plow EF, et al. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24 (7): 1591-601
9. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995 Jun 8; 332: 1553-9
10. Scarborough RM, Rose JW, Hsu MA, et al. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 1991 May 25; 266 (15): 9359-62
11. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993 Jan 15; 268 (2): 1066-73
12. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thromb Haemost 1997 Jul; 78: 214-9
13. Scarborough RM, Hsu MA, Teng W, et al. C68-22, a novel glycoprotein (GP) IIb-IIIa specific platelet aggregation inhibitor designed from the structure of harbourin [abstract]. Arterioscler Thromb 1991; 11: 1591a
14. McClellan KJ, Goa KL. Tirofiban: a review of its use in acute coronary syndrome. Drugs 1998 Nov; 56 (5): 1067-80
15. Charo F, Scarborough RM, du Mée CP, et al. Pharmacodynamics of the GPIIb-IIIa antagonist integrelin: phase I clinical studies in normal healthy volunteers. Circulation 1992 Oct; 86 Suppl. I: I-260
16. Kosoglou T, Belanger B, Alton KB, et al. Integrilin™ plasma concentration-response relationship of ex vivo platelet aggregation in healthy subjects [abstract no. P2857]. Eur Heart J 1997; 18 Suppl.: 492
17. Feuerstein G, Ruffolo JRR, Samanen J. The integrin alpha-II-beta-3 (GPIIb/IIIa): a target for novel anti-platelet drugs. Pharmacol Commun 1996; 8 (4): 257-65
18. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995 Dec 15; 76: 1222-7
19. Jennings L, Tardiff B, Phillips D, et al. Comparison of receptor occupancy and platelet aggregation response of eptifibatide administered intravenously in patients with unstable angina or non-Q-wave myocardial infarction [abstract]. J Am Coll Cardiol 1998 Feb; 31 Suppl. 2A: 93A
20. Unpublished data. COR Therapeutics Inc./Schering Plough Inc
21. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter trial. Circulation 1996 Nov 1; 94: 2083-9
22. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 1995 Apr 15; 91: 2151-7
23. PRIDE study results. Data on file, COR Therapeutics, Inc. Protocol no. 96-023, p. 40
24. Tcheng JE, Thel MC, Jennings L, et al. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose integrilin™ in coronary intervention. Results of the PRIDE study [abstract no. P3615]. Eur Heart J 1997 Aug; 18 Abs. Suppl.: 624
25. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997 Feb 18; 95: 846-54
26. Kosoglou T, Belanger B, Jennings L, et al. Eptifibatide pharmacokinetic-pharmacodynamic relationship in coronary angioplasty patients: results of the PRIDE study [abstract no. P486]. Eur Heart J 1997; 18 Suppl.: 52
27. Harrington RA, Schulman SP, Kleiman NS, et al. Profound, sustained and reversible platelet inhibition following administration of a glycoprotein IIb/IIIa inhibitor with and without heparin in patients with unstable angina [abstract]. Circulation 1994 Oct; 90 Part 2: 1-232
28. Harrington RA, Ohman EM, Sigmon KN, et al. Intensity of inhibition of the platelet glycoprotein IIb/IIIa receptor differs among disease states [abstract]. Circulation 1995 Oct 15; 92 Suppl. I: 488-9
29. 2+ on GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anti-coagulated with citrate. Circulation 1997 Sep 2; 96: 1488-94
30. Wells CR, Goldschmidt PJ, Coleman LD, et al. Platelet aggregation and fibrinogen binding in patients treated with integrelin and abciximab during coronary angioplasty [abstract]. J Am Coll Cardiol 1997 Feb; 29 Suppl. A: 241A
31. Van Wart S, Radwanski E, Kosoglou T, et al. The pharmacokinetics (PK) of Integrilin administered as an intravenous (IV) bous injection to healthy volunteers for optimization of antithrombotic therapy [abstract no. 3448]. Pharm Res 1997; 14 Suppl.: S-611
32. 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 1998 Mar-Apr; 20: 307-23
33. Van Wart S, Kosoglou T, Tcheng JE, et al. Eptifibatide pharmacokinetics in patients undergoing coronary angioplasty [abstract no. PIII-103]. Clin Pharmacol Ther 1998 Feb; 63 (2): 232
34. Sambol NC, Tcheng JE, Kitt M, et al. Population pharmacokinetics and pharmacodynamics of integrelin, a platelet aggregation inhibitor [abstract]. Clin Pharmacol Ther 1996 Feb; 59: 150
35. Cor Therapeutics Inc. Eptifibatide prescribing information. San Francisco
36. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997 May 17; 349: 1422-8
37. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998 Aug 13; 339 (7): 436-43
38. Higgins G. New data on GPIIb/IIIa receptor antagonist use in unstable angina. Inpharma 1997 Sep 27; 1106: 7-8
39. 39. Hughes S. Positive results for Integrilin in PURSUIT trial. Scrip 1997 Aug/2 Sep 29; 2262/63: 22-3
40. Harrington RA, Lincoff M, Berdan LG, et al. Maintenance of clinical benefit at six-months in patients treated with platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event [abstract no. 1887]. Circulation 1998 Oct 27; 98 Suppl.: I-359
41. Addendum to clinical study report. A randomized, double-blind evaluation of the efficacy and safety of Integrilin versus placebo for reducing mortality and myocardial (re)-infarction in patients with unstable angina or non-Q-wave myocardial infarction: six-month follow-up results. Protocol 94-106 PURSUIT Sep 24, 1998, unpublished data, COR Therapeutics Inc.
42. Alexander JH, Harrington RA, Guerci A, et al. Prior aspirin use potentiates the effect of GP IIb/IIIa inhibition in patients with non-ST elevation acute coronary syndromes [abstract]. J Am Coll Cardiol 1998 Feb; 31 Suppl. 2A: 93A
43. Lauer MA, Peterson JG, Arheart KL, et al. The effect of glycoprotein IIb/IIIa inhibition on rebound ischemia following discontinuation of heparin therapy: observations from the PURSUIT trial [abstract no. 4022]. Circulation 1998 Oct 27; 98 Suppl.: I-767
44. Snapshot of global cardiac care: women in Latin America and Eastern Europe don't fare as well. Presented at the 71st Scientific Session of the American Heart Association, Nov 1998
45. O'Shea C, Tcheng JE. Eptifibatide in coronary intervention: the IMPACT trials. In: Lincoff AM, Topol EJ, editors. Contemporary cardiology: platelet glycoprotein IIb/IIIa inhibitors in cardiovascular disease. Totowa, New Jersey: Humana Press, 1999: 115-26
46. Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Am J Cardiol 1997 Aug 18; 80: 21-8
47. Ronner E, van Kesteren HAM, Zijnen P, et al. Combined therapy with streptokinase and Integrilin [abstract]. J Am Coll Cardiol 1998 Feb; 31 Suppl. 2A: 191A
48. Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11 (1): 1-11
49. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82
50. Mandak JS, Blankenship JC, Gardner LH, et al. Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. J Am Coll Cardiol 1998 Jun; 31: 1518-24
51. Kleiman NS. Primary and secondary safety endpoints from IMPACT II. Am J Cardiol 1997 Aug 18; 80: 29-33
52. Schafer AI. Antiplatelet therapy. Am J Med 1996 Aug; 101: 199-209
53. Chong PH. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. Am J Health System Pharm 1998 Nov 15; 55: 2363-86
54. Brunelli C, Spallarossa P, Rossettin P, et al. Recognition and treatment of unstable angina. Drugs 1996 Aug; 52: 196-208
55. Théroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J 1997 Nov; 134 (5 Pt 2): 62-70
56. Faulds D, Sorkin EM. Abeiximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994; 48 (4): 583-98
57. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996 Aug 14; 78: 35-40
58. Rutsch W, Baumann G. Anticoagulation in interventional cardiology: optimizing patient outcome. Eur Heart J 1998; 19 Suppl. K: KII-7
59. Winkelmann BR, Zahn R, Stilz HU. Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary thrombosis. Expert Opin Invest Drug 1997 Nov; 6: 1623-42
60. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998 May 21; 338: 1498-505
61. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998 May 21; 338: 1488-97
62. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997 Sep 2: 96: 1445-53
63. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61
64. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96
65. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35
66. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use or platelet glycoprotein-IIb/IIIa blockade. Lancet 1998 Jul 11; 352: 87-92
67. Ferguson JJ, Lau TK. New antiplatelet agents for acute coronary syndromes. Am Heart J 1998 May; 135 Suppl.: S194-200
68. Mousa SA, Bennett JS. Platelets in health and disease: platelet GPIIb-IIIa structure and function: recent advances in anti-platelet therapy. Drugs Future 1996; 21 (11): 1141-54
69. Tonkin AM, Aroney CN. Guidelines for managing patients with unstable angina: rating the evidence and rationale for treatment. Med J Aust 1997 Jun 16; 166: 644-7
70. Catella-Lawson F, FitzGerald GA. Confusion in reperfusion: problems in the clinical development of antithrombotic drugs. Circulation 1997 Feb 18; 95: 793-5
71. Catella-Lawson F, FitzGerald GA. Trials in myocardial infarction. Reply [letter]. Circulation 1997 Nov 18; 96: 3815-6
72. Ohman EM, Califf RM, Topol EJ. Trials in myocardial infarction [letter]. Circulation 1997 Nov 18; 96: 3814-5
73. Todd C. Use GP IIb/IIIa receptor antagonists in acute coronary syndromes. PharmacoEcon Outcomes News 1998 Oct 3 (182): 3-4
74. Mark DB. The PURSUIT US economic substudy summary. Data on file, COR Therapeutics, Inc